Artemisinin Combination Therapy Market
Artemisinin Combination Therapy Market
Scope: Industry Analysis, Market Size,
Growth, Trends till 2030
Download Artemisinin Combination Therapy Market Report
Artemisinin Combination Therapy Market Size and Growth
The Artemisinin Combination Therapy (ACT) market has been experiencing steady growth due to the increasing prevalence of malaria, especially in regions like Africa and Asia. In 2023, the market size was valued at approximately USD 590 million, driven by the demand for effective antimalarial treatments. The growing awareness about the effectiveness of ACT in combating drug-resistant malaria strains has further boosted market expansion.
Companies Covered : (Covid-19 Impact Covered)
o KPC Pharmaceutical
o Shanghai Fosun Pharmaceutical Industrial Development
o Sanofi
o Desano Holdings
o Calyx Chemicals and Pharmaceuticals
o Mylan
o Novartis
o Denk Pharma
o Hovid Berhad
o Ipca Laboratories
o Cipla
o Aspen Pharmacare Holdings
o Ajanta Pharma
o Guilin Pharmaceuticals
The Artemisinin Combination Therapy (ACT) market has seen substantial growth, largely driven by the increasing prevalence of malaria, particularly in regions such as Africa and Southeast Asia. Major companies in this market include Novartis AG, Sanofi S.A., Cipla Ltd, Ipca Laboratories, and Mylan N.V. The COVID-19 pandemic impacted the market by disrupting supply chains and limiting access to essential malaria treatments.
Artemisinin Combination Therapy Market Segmentation
By Application
Hospital
Clinic
Other
By Product
• Artemether+Lumefantrine
• Artesunate+Amodiaquine
• Dihydroartemisinin+Piperaquine
• Artesunate+Mefloquine
• Artesunate+Sulfadoxine-Pyrimethamine
• Pyronaridine-Artesunate
• Other
Artemisinin
Combination Therapy Market Growth 2024-2030
$ X Billion USD
